Influence of Kidney Function on Risk of Supratherapeutic International Normalized Ratio-Related Hemorrhage in Warfarin Users: A Prospective Cohort Study

American Journal of Kidney Diseases

Volumn 65, Issue 5, 2015, Pages 701-709

  Limdi, Nita A ^a   Nolin, Thomas D ^b   Booth, Sarah L ^b   Centi, Amanda ^b   Marques, Marisa B ^c   Crowley, Michael R ^d   Allon, Michael ^e   Beasley, T Mark ^d  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

adverse event; chronic kidney disease (CKD); hemorrhage; Kidney function; pharmacokinetics; reversal of anticoagulation; supra therapeutic international normalized ratio (INR); warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; DECARBOXYPROTHROMBIN; PROTHROMBIN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; COHORT ANALYSIS; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATH ANALYSIS; PHARMACOGENETICS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK; AGED; CHEMICALLY INDUCED; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT;

AGED; ANTICOAGULANTS; FEMALE; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; WARFARIN;

EID: 84930007738     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.11.004     Document Type: Article

References (47)

1. A.K. Wittkowsky, and E.B. Devine Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin Pharmacotherapy 24 10 2004 1311 1316
2. E.M. Hylek, Y.C. Chang, S.J. Skates, R.A. Hughes, and D.E. Singer Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation Arch Intern Med 160 11 2000 1612 1617
3. E.M. Hylek, A.S. Go, Y. Chang, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 11 2003 1019 1026
4. D.S. Budnitz, M.C. Lovegrove, N. Shehab, and C.L. Richards Emergency hospitalizations for adverse drug events in older Americans N Engl J Med 365 21 2011 2002 2012
5. T.D. Nolin, J. Naud, F.A. Leblond, and V. Pichette Emerging evidence of the impact of kidney disease on drug metabolism and transport Clin Pharmacol Ther 83 6 2008 898 903
6. J.D. Momper, R. Venkataramanan, and T.D. Nolin Nonrenal drug clearance in CKD: searching for the path less traveled Adv Chronic Kidney Dis 17 5 2010 384 391
7. S.M. Huang, R. Temple, S. Xiao, L. Zhang, and L.J. Lesko When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective Clin Pharmacol Ther 86 5 2009 475 479
8. W. Ageno, A.S. Gallus, A. Wittkowsky, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 suppl 2012 e44S e88S
9. Warfarin [package insert]. US Food and Drug Administration. 2010. http://packageinserts.bms.com/pi/pi-coumadin.pdf. Accessed March 6, 2014.
10. N.A. Limdi, T.M. Beasley, M.F. Baird, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications J Am Soc Nephrol 20 2009 912 921
11. N.A. Limdi, M.A. Limdi, L. Cavallari, et al. Warfarin dosing in patients with impaired kidney function Am J Kidney Dis 56 5 2010 823 831
12. M.A. Limdi, M.R. Crowley, T.M. Beasley, N.A. Limdi, and M. Allon Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study Am J Kidney Dis 61 2 2013 354 357
13. N.A. Limdi, T.M. Beasley, M.R. Crowley, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans Pharmacogenomics 9 10 2008 1445 1458
14. N.A. Limdi, G. McGwin, J.A. Goldstein, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin Clin Pharmacol Ther 83 2 2008 312 321
15. A.S. Levey, L.A. Stevens, C.H. Schmid, et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612
16. A.S. Levey, and L.A. Stevens Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions Am J Kidney Dis 55 4 2010 622 627
17. E.M. Hylek, S.J. Skates, M.A. Sheehan, and D.E. Singer An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation N Engl J Med 335 8 1996 540 546
18. S.D. Fihn, M. McDonell, D. Martin, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group Ann Intern Med 118 7 1993 511 520
19. T.M. Therneau, and P.M. Grambsch Multiple events per subject In: T.M. Therneau, P.M. Grambsch, eds. Modeling Survival Data: Extending the Cox Model (Statistics for Biology and Health) 2001 Springer-Verlag New York, NY 169 229
20. S.D. Fihn, C.M. Callahan, D.C. Martin, M.B. McDonell, J.G. Henikoff, and R.H. White The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics Ann Intern Med 124 11 1996 970 979
21. E.M. Hylek, S. Regan, A.S. Go, R.A. Hughes, D.E. Singer, and S.J. Skates Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin Ann Intern Med 135 6 2001 393 400
22. J.D. Lindh, L. Holm, M.L. Dahl, L. Alfredsson, and A. Rane Incidence and predictors of severe bleeding during warfarin treatment J Thromb Thrombolysis 25 2 2008 151 159
23. G. Palareti, and B. Cosmi Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients Thromb Haemost 102 2 2009 268 278
24. S. Shalansky, L. Lynd, K. Richardson, A. Ingaszewski, and C. Kerr Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis Pharmacotherapy 27 9 2007 1237 1247
25. J.P. DiMarco, G. Flaker, A.L. Waldo, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study Am Heart J 149 4 2005 650 656
26. A. Holbrook, S. Schulman, D.M. Witt, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 suppl 2012 e152S e184S
27. M.A. Crowther, W. Ageno, D. Garcia, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial Ann Intern Med 150 5 2009 293 300
28. T.-M. Duong, B.K. Plowman, A.P. Morreale, and K. Janetzky Retrospective and prospective analyses of the treatment of overanticoagulated patients Pharmacotherapy 18 6 1998 1264 1270
29. J.J. Glover, and G.B. Morrill Conservative treatment of overanticoagulated patients Chest 108 4 1995 987 990
30. 1 in these reactions Biochem J 194 3 1981 983 988
31. R. Wallin, and L.F. Martin Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin J Clin Invest 76 5 1985 1879 1884
32. R. Wallin, and S.M. Hutson Warfarin and the vitamin K-dependent gamma-carboxylation system Trends Mol Med 10 7 2004 299 302
33. M.D. Crosier, I. Peter, S.L. Booth, G. Bennett, B. Dawson-Hughes, and J.M. Ordovas Association of sequence variations in vitamin K epoxide reductase and gamma-glutamyl carboxylase genes with biochemical measures of vitamin K status J Nutr Sci Vitaminol 55 2 2009 112 119
34. M.A. Rishavy, and K.L. Berkner Vitamin K oxygenation, glutamate carboxylation, and processivity: defining the three critical facets of catalysis by the vitamin K-dependent carboxylase Adv Nutr 3 2 2012 135 148
35. M.J. Shearer, X. Fu, and S.L. Booth Vitamin K nutrition, metabolism, and requirements: current concepts and future research Adv Nutr 3 2 2012 182 195
36. L.V. Tsu, J.E. Dienes, and W.E. Dager Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting Ann Pharmacother 46 12 2012 1617 1626
37. S. Umeki, and Y. Umeki Levels of acarboxy prothrombin (PIVKA-II) and coagulation factors in warfarin-treated patients Med Lab Sci 47 2 1990 103 107
38. Abdelhafez OM, Amin KM, Batran RZ, Maher TJ, Nada SA, Sethumadhavan S. Synthesis, anticoagulant and PIVKA-II induced by new 4-hydroxycoumarin derivatives. Bioorg Med Chem. 2010;18(10):3371-3378.
39. V. Pichette, and F.A. Leblond Drug metabolism in chronic renal failure Curr Drug Metab 4 2 2003 91 103
40. C.K. Yeung, D.D. Shen, K.E. Thummel, and J. Himmelfarb Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport Kidney Int 85 3 2014 522 528
41. A.W. Dreisbach, and J.J. Lertora The effect of chronic renal failure on hepatic drug metabolism and drug disposition Semin Dial 16 1 2003 45 50
42. F. Leblond, C. Guevin, C. Demers, I. Pellerin, M. Gascon-Barre, and V. Pichette Downregulation of hepatic cytochrome P450 in chronic renal failure J Am Soc Nephrol 12 2 2001 326 332
43. P.Y. Boxma, E. van den Berg, J.M. Geleijnse, et al. Vitamin K intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients PloS One 7 10 2012 e47991
44. G. Schlieper, R. Westenfeld, T. Kruger, et al. Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD J Am Soc Nephrol 22 2 2011 387 395
45. K. Voong, D. Harrington, and D. Goldsmith Vitamin K status in chronic kidney disease: a report of a study and a mini-review Int Urol Nephrol 45 5 2013 1339 1344
46. J.I. Shen, M.P. Turakhia, and W.C. Winkelmayer Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? Curr Opin Nephrol Hypertens 21 6 2012 600 606
47. J.I. Shen, M.E. Montez-Rath, T.I. Chang, and W.C. Winkelmayer Warfarin initiation after newly-diagnosed atrial fibrillation associates with better outcomes in U.S. patients on hemodialysis (abstract FR-OR138) J Am Soc Nephrol 24 2013